Here are five points:
1. The firm has a $65 price objective on NuVasive’s stock, up from their previous price objective of $60.
2. NuVasive currently has an average rating of buy and an average target price of $58.63.
3. NuVasive has a 12-month low of $41.52 and a 12-month high of $56.61.
4. T he stock’s 50 day moving average price is $50.44 and its 200-day moving average price is $50.81.
5. The stock has a market capitalization of $2.51 billion.
More articles on devices:
Grab some rays — Active individuals may need to maintain higher vitamin D levels to minimize stress fracture risk
Houston Methodis Hospital implements CT-free robotic surgery — 5 key points
OrthoSensor raises $3.9M in funding: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
